中国医药科学2024，Vol.14Issue(12)：51-54,4.DOI:10.20116/j.issn2095-0616.2024.12.12
胰高糖素样肽-1受体激动剂临床应用合理性和安全性分析
Clinical application rationality and safety analysis of glucagon like peptide-1 receptor agonist
摘要
Abstract
Objective To investigate the status of inpatients undergoing treatment with glucagon like peptide-1 receptor agonist(GLP-1RA),understand the current application status and adverse reactions of this type of drugs,and analyze its risk factors,so as to provide basis for standardizing its clinical rational application.Methods The authoritative guidelines,clinical research and expert consensus of GLP-1RA at home and abroad were summarized,and the rationality evaluation criteria of GLP-1RA clinical application with the instructions was formed.The medical records of inpatients using GLP-1RA in the Second Affiliated Hospital of Guangzhou Medical University from January 2021 to April 2023 were retrospectively collected,and the rationality and safety were analyzed according to the established evaluation criteria,and suggestions for rational medication were put forward.Results A total of 261 patients were treated with GLP-1RA,including 258 effective cases and 160 cases of irrational medication,with a rate of 62.02％.The main reasons were irrational medication beyond indications and inappropriate usage and dosage.There were 3 cases of adverse reactions,with an incidence rate of 1.16％,mainly including hypoglycemia and elevated transaminases.During clinical medication,more attention to patients'blood glucose and liver and kidney function indices,and the indications,usage and dosage,contraindications and combined medication of GLP-1RA should be paid.Conclusion The hypoglycemic,weight loss and cardiovascular protective effects of GLP-1RA have attracted much attention.The problems and ADRs in doctors'clinical practice of using GLP-1RA are aimed in this study,and concrete and feasible guidance and suggestions are provided to promote the rational use of GLP-1RA.关键词
胰高糖素样肽-1受体激动剂/评价标准/不良反应/2型糖尿病/减重Key words
Glucagon like peptide-1 receptor agonist/Evaluation criteria/Adverse reactions/Type 2 diabetes/Weight loss分类
医药卫生引用本文复制引用
罗银龙,曾彩芳,罗柳金..胰高糖素样肽-1受体激动剂临床应用合理性和安全性分析[J].中国医药科学,2024,14(12):51-54,4.基金项目
广东省广州市卫生健康科技一般引导项目(20231A010055). （20231A010055）
